menu
    • menu
    [{"orgOrder":0,"company":"Biossil","sponsor":"Galera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Avasopasem manganese","moa":"SOD1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Biossil","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Biossil \/ Biossil","highestDevelopmentStatusID":"10","companyTruncated":"Biossil \/ Biossil"},{"orgOrder":0,"company":"Biossil","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Remetinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Biossil","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Gel","sponsorNew":"Biossil \/ Biossil","highestDevelopmentStatusID":"8","companyTruncated":"Biossil \/ Biossil"},{"orgOrder":0,"company":"Biossil","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Senicapoc","moa":"Intermediate conductance calcium-activated potassium channel protein 4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biossil","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biossil \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biossil \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Biossil

    Menu

    Biossil

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biossil

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Biossil

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Senicapoc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

                            Details : SIL-8301 (Senicapoc) is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Anemia, Sickle Cell.

                            Product Name : SIL-8301

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 15, 2025

                            Lead Product(s) : Senicapoc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biossil

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Biossil

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Medivir

                            Deal Size : $60.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medivir Enters Exclusive Licensing Agreement with Biossil for Remetinostat

                            Details : Through the licensing deal for Remetinostat, targeting HDAC, the agreement aims to advance treatment options for Basal cell carcinoma (BCC).

                            Product Name : SHP-141

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 23, 2025

                            Lead Product(s) : Remetinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Medivir

                            Deal Size : $60.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biossil

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Biossil

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avasopasem manganese

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Galera Therapeutics

                            Deal Size : $108.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biossil Acquires Galera’s Dismutase Mimetics Portfolio for $105M

                            Details : Through the acquisition of Avasopasem Manganese, the deal aims to advance treatment options for metaplastic breast cancer.

                            Product Name : GC4419

                            Product Type : Miscellaneous

                            Upfront Cash : $3.5 million

                            October 22, 2025

                            Lead Product(s) : Avasopasem manganese

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Galera Therapeutics

                            Deal Size : $108.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.